SCHEMBL1752204

SCHEMBL1752204

COC(=O)c1ccc(-c2cc(Cl)c(C(=O)N3CCC4(CCC(O[Si](c5ccccc5)(c5ccccc5)C(C)(C)C)CC4)C3)c(Cl)c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 1/20 0.37
BACE1 P56817 1/20 0.36
SPR P35270 8/20 0.36
USP2 O75604 6/20 0.35
HSD17B10 Q99714 5/20 0.35
CYP2C9 P11712 4/20 0.35
HIF1A Q16665 3/20 0.35
MAPK1 P28482 3/20 0.35
CYP2C19 P33261 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
TP53 P04637 1/20 0.35
CYP2D6 P10635 1/20 0.35
TSHR P16473 1/20 0.35
ALDH1A1 P00352 5/20 0.35
CYP1A2 P05177 5/20 0.35
CYP3A4 P08684 5/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ABL1 P00519 1/20 0.35
SCD5 Q86SK9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1750497 0.93 BACE1 (0.37) BACE1SPRUSP2HSD17B10CYP2C9
SCHEMBL1750769 0.81 SPR (0.38) BACE1SPRSCD5CCR5
SCHEMBL1751026 0.78 SPR (0.55) SPRUSP2HSD17B10CYP2C9HIF1A
SCHEMBL1752202 0.78 BACE1 (0.39) CHRM4BACE1SMN1; SMN2ALDH1A1MEN1
SCHEMBL12386297 0.72 TNKS (0.39) CHRM4
SCHEMBL2301573 0.72 CHRM4 (0.37) CHRM4BACE1SMN1; SMN2ALDH1A1CYP3A4
SCHEMBL1750496 0.70 BACE1 (0.40) BACE1
SCHEMBL30942977 0.69 BACE1 (0.41) BACE1CYP2C9CYP2C19SMN1; SMN2TSHR
SCHEMBL31565550 0.69 CYP11B2 (0.45) BACE1USP2CYP2C9HIF1AMAPK1
SCHEMBL31565549 0.69 CYP11B2 (0.45) BACE1USP2CYP2C9HIF1AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968585-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2011-06-28 US disclosed
EP-2035379-B1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2010-06-16 EP disclosed
US-20090099180-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-04-16 US disclosed
EP-2035379-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 Eli Lilly & Company (US) 2009-03-18 EP disclosed
WO-2007127763-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099180-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD11B2, HSD3B1 CHRM4 4658/4885BACE1 155/4885SPR 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.